Industry

Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or … [Read more…]

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the … [Read more…]

NUBEQA now has indications in both metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)1 Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall survival (OS) benefit with NUBEQA plus androgen deprivation therapy (ADT) and docetaxel compared … [Read more…]

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stock at a price of $63.85 per share to the underwriter, which includes the … [Read more…]

New formulation can be co-administered with gastric acid-reducing agents Tablet offers efficacy, safety and consistent dosing compared to current capsule WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s new tablet formulation of CALQUENCE® (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and for patients with … [Read more…]

CINCINNATI–(BUSINESS WIRE)–Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company’s capital stock, payable on September 2, 2022, to shareholders of record as of August 15, 2022. This is a 2-cent, or 5.6%, increase over the 36-cent dividend paid in June 2022. … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Genital Herpes Treatment Market – Global Outlook and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global genital herpes treatment market is expected to grow at a CAGR of 3.76% during 2022-2028 The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, … [Read more…]

LOS ANGELES–(BUSINESS WIRE)–Westlake Financial partnered with Ronald McDonald’s 2022 Walk for Kids and donated $72K, one of the largest donations in Southern California thus far. The Walk for Kids is motivated to create a community of hope and healing for critically ill children and their loved ones. “Westlake understands the importance of strength in a … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Gene Therapy Market by Type of Therapy, Type of Gene Delivery Method Used, Type of Vector Used, Target Therapeutic Areas, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering. Gene Therapy Market (5th Edition) report features an extensive study of the current … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Hepatitis C Tests Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030” report has been added to ResearchAndMarkets.com’s offering. The model discusses in detail the impact of COVID-19 on Hepatitis C Tests market for the year 2020 and beyond. Hepatitis C is … [Read more…]